CRISPR Therapeutics (NASDAQ: CRSP) made a name for itself by pioneering advanced gene therapies made with technologies that ...

It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.

ZUG, Switzerland and BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRSP), a biopharmaceutical company focused on ...

Using CRISPR, the popular gene-editing tool, scientists bumped up the fruit’s sugar content by 30 percent without sacrificing ...

In a groundbreaking study published in the journal Nature, researchers have successfully used gene editing to create sweeter ...

They realized that if they “release” these breaks, tomatoes could become much sweeter. They used CRISPR-Cas9 gene-editing ...

Harvard researchers pioneered a method called HACE for targeted gene mutations, advancing genetic research potential.

Glucose and fructose levels were 30 per cent higher after researchers removed two genes that regulate sugar content, ...

Researchers used base and prime editing to uncover new EGFR gene mutations that affect cancer progression and drug resistance ...

Orsini has been chosen by Vertex Pharmaceuticals Incorporated to dispense gene-editing therapy CASGEVY® (exagamglogene autotemcel). CASGEVY is a CRISPR/Cas9 gene-edited cell therapy indicated for the ...

ETH Zurich researchers explored genetic mutations’ effects on cell function and their role in cancer development and treatment using CRISPR/Cas techniques.

Citi initiates coverage of Gilead Sciences and Vertex Pharmaceuticals at buy in the large U.S. biotech sector. Read more here.